Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. LaRosa JC, et al. Among authors: wenger nk. N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Free article. Clinical Trial.
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers.
Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; Treating to New Targets (TNT) Investigators. Arsenault BJ, et al. Among authors: wenger nk. PLoS One. 2014 Dec 22;9(12):e114519. doi: 10.1371/journal.pone.0114519. eCollection 2014. PLoS One. 2014. PMID: 25531109 Free PMC article. Clinical Trial.
C-reactive protein and coronary heart disease.
Foody JM, Gotto AM, Wenger N. Foody JM, et al. N Engl J Med. 2004 Jul 15;351(3):295-8; author reply 295-8. N Engl J Med. 2004. PMID: 15257565 No abstract available.
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; TNT Study Investigators. Arsenault BJ, et al. Among authors: wenger nk. J Am Coll Cardiol. 2011 Jan 4;57(1):63-9. doi: 10.1016/j.jacc.2010.06.052. J Am Coll Cardiol. 2011. PMID: 21185503 Free article. Retracted. Clinical Trial.
Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).
Shepherd J, Breazna A, Deedwania PC, LaRosa JC, Wenger NK, Messig M, Wilson DJ; Treating to New Targets Steering Committee and Investigators. Shepherd J, et al. Among authors: wenger nk. Am J Cardiol. 2016 Apr 15;117(8):1199-205. doi: 10.1016/j.amjcard.2016.01.014. Epub 2016 Jan 28. Am J Cardiol. 2016. PMID: 26940556 Free article.
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; Treating to New Targets Investigators. Shepherd J, et al. Among authors: wenger nk. Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-9. doi: 10.2215/CJN.04371206. Epub 2007 Oct 17. Clin J Am Soc Nephrol. 2007. PMID: 17942759 Clinical Trial.
604 results